‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
Reports and Proceedings
Welcome to the American Chemical Society (ACS) News Page.
Below are the latest press releases and news briefs from ACS.
For more information, visit the ACS website or the Resources tab above.
Updates every hour. Last Updated: 2-Jul-2025 06:10 ET (2-Jul-2025 10:10 GMT/UTC)
Early animal studies show that a single vaccine could protect the recipient from different variants of the coronaviruses that cause COVID-19, the flu and the common cold. In addition to creating antibodies that target a specific region of the spike protein that doesn’t mutate, the vaccine removes the sugar coat from the virus that allows it to hide in the body. The researcher will present his results at the ACS Spring 2025 Digital Meeting.
The condition of the grass on a golf course can drastically skew the chances of a winning putt regardless of a player’s skill. Now, a coating that soaks up water molecules could slow the roll of a golf ball on a lightning-fast, dry course and speed it up on a sluggish, wet course without interfering with the ball when it’s airborne. The researcher will present his results at ACS Spring 2025.
When wildfires threaten communities, human health can be impacted as smoke distributes on the breeze, infiltrating various structures. To help people protect themselves and their families, researchers have developed a low-cost, durable, do-it-yourself air filtration system that works as well as more expensive HEPA filters to clear indoor air pollutants such as smoke — or possibly limit the impact of airborne disease spread. They will present their results at the ACS Spring 2025 Digital Meeting.
Dogs have many jobs but one you may not expect is identifying grapevines with a destructive and highly contagious fungus called powdery mildew. Researchers are analyzing volatile chemicals emanating from grape leaves infected by powdery mildew, with the goal of improving training for vineyard canines. The researchers will present their results at ACS Spring 2025.
GLP-1 receptor agonists are peptide-based drugs used for managing diabetes and for weight loss, but these treatments have had shortages recently. Now, through a process called in vivo antibody painting, researchers have attached GLP-1 receptor agonists to antibodies through a reaction that happens inside the body, increasing the drug’s stability. In animal models, a single dose works better and lasts longer than currently administered dosages. The researchers will present their results at ACS Spring 2025.